SCHEMBL6084965

SCHEMBL6084965

Cc1ccc2oc(-c3c[nH]nc3-c3cccc(NC(=O)C(C)C)c3)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
USP2 O75604 3/20 0.60
POLB P06746 1/20 0.60
TP53 P04637 6/20 0.57
HPGD P15428 5/20 0.57
ALDH1A1 P00352 5/20 0.57
HSD17B10 Q99714 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
GAA P10253 2/20 0.57
THRB P10828 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MAPT P10636 2/20 0.55
KMT2A Q03164 2/20 0.52
UTRN P46939 1/20 0.52
MEN1 O00255 1/20 0.52
P2RY14 Q15391 1/20 0.52
DUSP1 P28562 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086892 0.91 USP2 (0.74) KDM4EUSP2POLBTP53HPGD
SCHEMBL6086040 0.90 TP53 (0.52) KDM4EUSP2POLBTP53HPGD
SCHEMBL6085509 0.90 SMN1; SMN2 (0.63) KDM4EUSP2TP53HPGDALDH1A1
SCHEMBL6087043 0.90 AGPAT2 (0.58) KDM4EUSP2POLBTP53HPGD
SCHEMBL6085505 0.89 TP53 (0.56) KDM4EUSP2POLBTP53HPGD
SCHEMBL6086053 0.87 AGPAT2 (0.64) KDM4EPOLBTP53HPGDALDH1A1
SCHEMBL6085011 0.87 TP53 (0.52) KDM4EUSP2POLBTP53HPGD
SCHEMBL6085928 0.86 TP53 (0.53) KDM4EUSP2TP53HPGDALDH1A1
SCHEMBL6087314 0.85 HPGD (0.54) KDM4EUSP2POLBTP53HPGD
SCHEMBL6085428 0.85 P2RY14 (0.69) KDM4EUSP2POLBTP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 KDM4E 1175/4885USP2 2427/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.